Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × pCR Rate × Epirubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 90 Triple Negative Breast Neoplasms 18 Stomach Neoplasms 14 Inflammatory Breast Neoplasms 12 Esophageal Neoplasms 7 Lymphoma, Large B-Cell, Diffuse 5 Testicular Neoplasms 3 Pancreatic Neoplasms 3 Lymphoma 3 Adenocarcinoma Of Esophagus 3 Urinary Bladder Neoplasms 2 Sarcoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Ovarian Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2 Neoplasms 2 Lymphoma, B-Cell, Marginal Zone 2 Carcinoma, Hepatocellular 2 Breast Neoplasms, Male 2 pCR Rate 1 Women With Primary Breast Cancer 1 Upper Tract Urothelial Carcinoma 1 Unilateral HER2 Positive Breast Cancer 1 Thymoma 1 Testicular Germ Cell Tumor 1 Small Cell Lung Cancer Extensive Stage 1 Rare Tumour 1 Prostatic Neoplasms 1 Primary Breast Cancer 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Metformin 1 Epirubicin 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01929811 2022-04-06

NeoMET

Shanghai Jiao Tong University School of Medicine

Phase 2 Terminated

pCR Rate

Data powered by HemOnc (CC BY 4.0) Colophon ⚡